Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca and Innate Pharma ally on cancer drug development

AstraZeneca and Innate Pharma ally on cancer drug development

27th April 2015

AstraZeneca and its subsidiary MedImmune are entering into a new drug development alliance with Innate Pharma.

The collaboration aims to accelerate and broaden the development of Innate Pharma's proprietary anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune.

Currently in phase II development, IPH2201 will be studied both as a monotherapy and in combination with currently approved treatments across a range of cancers, addressing multiple immune pathways.

AstraZeneca will make an initial payment to Innate of $250 million (165.11 million pounds), plus a further $100 million prior to initiation of phase III development, as well as additional regulatory and sales-related milestones.

Pascal Soriot, chief executive officer of AstraZeneca, said: "We are pleased to collaborate with Innate Pharma to bring this prospective first-in-class treatment to cancer patients, further strengthening our broad immuno-oncology pipeline."

The firm previously announced an immuno-oncology partnership with Omnis Pharmaceuticals earlier this year.ADNFCR-8000103-ID-801785149-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.